Once Weekly Parathyroid Hormone for Osteoporosis

Completed · Phase 3 · Has a placebo group

Conditions studied: Osteopenia, Osteoporosis

In brief

Daily parathyroid hormone (PTH) is approved by the FDA for the treatment of osteoporosis. This study will evaluate the safety and effectiveness of PTH when given once a week.

Key facts

Study ID

NCT00065637

Run by

University of California, San Francisco

People needed

50

Starts

2003-12-01

Expected to finish

2005-09-01

Last updated by the study team

2013-02-05

Who can join

Age: 45 and older, up to 70. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• Bone mineral density scan with a T-score between -1 and -2
• Willing to self-administer injections
• Postmenopausal

You may not qualify if…

• Medications to treat osteoporosis, including: hormone replacement therapy for more than one month in the 6 months prior to study, or for more than 12 months in the 2 years prior to study; alendronate, risedronate, or etidronate for more than 1 year anytime prior to study; calcitonin in the 3 months prior to study; taken raloxifene or tamoxifen in the last 6 months or for more than 1 year in the 2 years prior to study; fluoride for more than 1 month in the 5 years prior to study
• Bone fracture since menopause
• Femoral neck T-score below -2 AND lumbar spine T-score below -2.5 OR femoral neck T-score below -2.5 AND T-scores of both total hip and lumbar spine below -2

Where it is running

• St Joseph Hospital — Bangor, Maine, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.